Abstract
This study was conducted on 50 cases of prostate cancer patients and 20 apparently healthy. The study analyzed the distribution of prostate cancer (PC) patients across various categories. Significant differences were observed in group grades, Gleason scores, cell grades, stages, and dose names. The mean age of the patient cohort was 67.84 years with a median diagnosis time of 7 years. Laboratory assays including measurements of red blood cells count, platelet count, white blood cells count, and prostate specific antigene levels. The mean total chemotherapy dose received by patients was 1708.28. Significant differences were found in the distribution of group grades, cell grades, and Gleason scores between patients who have chemotherapy and those untreated. No significant differences in the stage distribution. Comparisons of laboratory assay results between chemotherapy-treated and untreated patients revealed significant differences in diagnosis time. However, no significant differences were noted in RBC count, PLT count, WBC count, and PSA levels. Chemotherapy significantly downregulated the expression of Notch1. Untreated patients have a higher Notch1 expression (median = 2.68) compared to treated patients (median = 0.60).Notch1 has a low expression with Zometa & Taxoter treatments compared to more extensive drug regimens (p<0.001).
Recommended Citation
Khudhur, Mustafa S. and Majeed, Ali Adil
(2024)
"An Evaluation of Notch-1 Gene Expression as a Prognostic, Diagnostic, and Treatment Efficacy Marker in Iraqi Prostate Cancer Patients,"
Al-Ameed Journal for Medical Research and Health Sciences: Vol. 2
:
Iss.
1
, Article 4.
Available at:
https://doi.org/10.61631/3005-3188.1014